Belite Bio On A Tear As It Approaches Key Regulatory Submissions
Source: SeekingAlpha
2026-01-27 12:41:35 ET
The market has definitely started to care more about Belite Bio ( BLTE ) in the last few months, as the shares of this ophthalmology-focused biotech have risen roughly 150% since late September. The stock has likewise started attracting the attention of larger sell-side research firms, raising its profile even further ahead of key regulatory submissions in 2026....
Read the full article on Seeking Alpha
For further details see:
Belite Bio On A Tear As It Approaches Key Regulatory Submissions
Annexon Inc.
NASDAQ: ANNX
ANNX Trading
8.65% G/L:
$5.47 Last:
1,131,076 Volume:
$5.02 Open:
ANNX Latest News
February 24, 2026 08:00:00 am
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
February 17, 2026 08:00:00 am
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
ANNX Stock Data
$671,140,030
105,432,390
8.18%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
Brisbane
